Annual CFF
-$1.79 B
-$781.10 M-77.41%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual cash flow from financing activities is currently -$1.79 billion, with the most recent change of -$781.10 million (-77.41%) on 31 December 2023. During the last 3 years, it has fallen by -$784.30 million (-77.98%). REGN annual CFF is now -565.87% below its all-time high of $384.25 million, reached on 31 December 2011.REGN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$634.00 M
-$155.90 M-32.61%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly cash flow from financing activities is currently -$634.00 million, with the most recent change of -$155.90 million (-32.61%) on 30 September 2024. Over the past year, it has dropped by -$187.90 million (-42.12%). REGN quarterly CFF is now -203.59% below its all-time high of $612.00 million, reached on 30 September 2020.REGN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$1.51 B
-$226.70 M-17.65%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM cash flow from financing activities is currently -$1.51 billion, with the most recent change of -$226.70 million (-17.65%) on 30 September 2024. Over the past year, it has increased by +$279.00 million (+15.59%). REGN TTM CFF is now -493.26% below its all-time high of $384.25 million, reached on 31 December 2011.REGN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -42.1% | +15.6% |
| 3 y3 years | -78.0% | +30.1% | -50.2% |
| 5 y5 years | -610.1% | -83.4% | -499.4% |
REGN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -78.0% | at low | -1079.9% | +30.1% | -171.0% | +20.9% |
| 5 y | 5 years | -610.1% | +9.2% | -203.6% | +75.7% | -4051.4% | +43.5% |
| alltime | all time | -565.9% | +9.2% | -203.6% | +75.7% | -493.3% | +43.5% |
Regeneron Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$634.00 M(+32.6%) | -$1.51 B(+17.7%) |
| June 2024 | - | -$478.10 M(-1115.1%) | -$1.28 B(-9.6%) |
| Mar 2024 | - | $47.10 M(-110.6%) | -$1.42 B(-20.6%) |
| Dec 2023 | -$1.79 B(+77.4%) | -$446.10 M(+9.5%) | -$1.79 B(+12.5%) |
| Sept 2023 | - | -$407.30 M(-33.7%) | -$1.59 B(-16.6%) |
| June 2023 | - | -$614.20 M(+90.4%) | -$1.91 B(+36.7%) |
| Mar 2023 | - | -$322.50 M(+30.3%) | -$1.40 B(+38.4%) |
| Dec 2022 | -$1.01 B(+0.3%) | -$247.60 M(-65.8%) | -$1.01 B(-39.5%) |
| Sept 2022 | - | -$725.00 M(+617.1%) | -$1.67 B(+199.1%) |
| June 2022 | - | -$101.10 M(-256.3%) | -$557.60 M(-3.0%) |
| Mar 2022 | - | $64.70 M(-107.1%) | -$574.70 M(-42.9%) |
| Dec 2021 | -$1.01 B(-49.0%) | -$906.60 M(-335.2%) | -$1.01 B(+148.7%) |
| Sept 2021 | - | $385.40 M(-426.1%) | -$404.50 M(+127.4%) |
| June 2021 | - | -$118.20 M(-67.7%) | -$177.90 M(-93.3%) |
| Mar 2021 | - | -$366.40 M(+20.0%) | -$2.67 B(+35.6%) |
| Dec 2020 | -$1.97 B(+681.6%) | -$305.30 M(-149.9%) | -$1.97 B(-2.0%) |
| Sept 2020 | - | $612.00 M(-123.4%) | -$2.01 B(-23.7%) |
| June 2020 | - | -$2.61 B(-878.5%) | -$2.63 B(+7136.0%) |
| Mar 2020 | - | $335.60 M(-197.1%) | -$36.40 M(-85.6%) |
| Dec 2019 | -$252.10 M(+227.0%) | -$345.70 M(+3042.7%) | -$252.10 M(-2478.3%) |
| Sept 2019 | - | -$11.00 M(-28.1%) | $10.60 M(-58.1%) |
| June 2019 | - | -$15.30 M(-112.8%) | $25.30 M(-13.9%) |
| Mar 2019 | - | $119.90 M(-244.5%) | $29.40 M(-138.1%) |
| Dec 2018 | -$77.10 M(+216.0%) | -$83.00 M(-2343.2%) | -$77.10 M(-62.3%) |
| Sept 2018 | - | $3.70 M(-133.0%) | -$204.63 M(-5.5%) |
| June 2018 | - | -$11.20 M(-183.6%) | -$216.53 M(+201.5%) |
| Mar 2018 | - | $13.40 M(-106.4%) | -$71.81 M(+194.3%) |
| Dec 2017 | -$24.40 M(-96.5%) | -$210.53 M(+2468.8%) | -$24.40 M(-92.0%) |
| Sept 2017 | - | -$8.20 M(-106.1%) | -$305.65 M(+13.7%) |
| June 2017 | - | $133.52 M(+119.6%) | -$268.78 M(-38.0%) |
| Mar 2017 | - | $60.81 M(-112.4%) | -$433.50 M(-38.1%) |
| Dec 2016 | -$700.50 M(+166.6%) | -$491.79 M(-1815.0%) | -$700.50 M(+229.3%) |
| Sept 2016 | - | $28.68 M(-191.9%) | -$212.72 M(-63.8%) |
| June 2016 | - | -$31.20 M(-84.9%) | -$587.04 M(+4.9%) |
| Mar 2016 | - | -$206.19 M(+5044.5%) | -$559.38 M(+112.9%) |
| Dec 2015 | -$262.80 M(+20.2%) | -$4.01 M(-98.8%) | -$262.80 M(-48.6%) |
| Sept 2015 | - | -$345.65 M(+9677.9%) | -$511.44 M(+218.4%) |
| June 2015 | - | -$3.54 M(-103.9%) | -$160.63 M(-32.3%) |
| Mar 2015 | - | $90.40 M(-135.8%) | -$237.10 M(+8.5%) |
| Dec 2014 | -$218.55 M(-402.7%) | -$252.66 M(-4990.7%) | -$218.55 M(-262.2%) |
| Sept 2014 | - | $5.17 M(-106.5%) | $134.72 M(+1.2%) |
| June 2014 | - | -$80.01 M(-173.4%) | $133.09 M(-21.5%) |
| Mar 2014 | - | $108.95 M(+8.3%) | $169.62 M(+135.0%) |
| Dec 2013 | $72.19 M(-173.9%) | $100.62 M(+2747.9%) | $72.19 M(-171.2%) |
| Sept 2013 | - | $3.53 M(-108.1%) | -$101.44 M(-5.0%) |
| June 2013 | - | -$43.48 M(-477.3%) | -$106.78 M(+56.2%) |
| Mar 2013 | - | $11.52 M(-115.8%) | -$68.37 M(-30.0%) |
| Dec 2012 | -$97.65 M(-125.4%) | -$73.01 M(+3935.9%) | -$97.65 M(-129.0%) |
| Sept 2012 | - | -$1.81 M(-64.4%) | $336.80 M(-0.5%) |
| June 2012 | - | -$5.08 M(-71.4%) | $338.33 M(-4.3%) |
| Mar 2012 | - | -$17.75 M(-104.9%) | $353.46 M(-8.0%) |
| Dec 2011 | $384.25 M(+57.9%) | $361.44 M(<-9900.0%) | $384.25 M(+86.9%) |
| Sept 2011 | - | -$279.00 K(-102.8%) | $205.57 M(-0.9%) |
| June 2011 | - | $10.05 M(-22.9%) | $207.46 M(+3.7%) |
| Mar 2011 | - | $13.04 M(-92.9%) | $200.13 M(-17.7%) |
| Dec 2010 | $243.31 M(+675.8%) | $182.76 M(>+9900.0%) | $243.31 M(+193.6%) |
| Sept 2010 | - | $1.61 M(-40.7%) | $82.88 M(-0.6%) |
| June 2010 | - | $2.72 M(-95.2%) | $83.41 M(+2.5%) |
| Mar 2010 | - | $56.22 M(+151.8%) | $81.36 M(+159.4%) |
| Dec 2009 | $31.36 M(-116.3%) | $22.33 M(+939.5%) | $31.36 M(-129.4%) |
| Sept 2009 | - | $2.15 M(+222.0%) | -$106.68 M(-0.8%) |
| June 2009 | - | $667.00 K(-89.3%) | -$107.51 M(-43.0%) |
| Mar 2009 | - | $6.22 M(-105.4%) | -$188.54 M(-2.2%) |
| Dec 2008 | -$192.86 M | -$115.72 M(-8840.1%) | -$192.86 M(-181.3%) |
| Sept 2008 | - | $1.32 M(-101.6%) | $237.09 M(+0.4%) |
| June 2008 | - | -$80.37 M(-4323.1%) | $236.11 M(-26.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $1.90 M(-99.4%) | $319.35 M(-0.0%) |
| Dec 2007 | $319.40 M(+72.3%) | $314.23 M(>+9900.0%) | $319.40 M(+72.4%) |
| Sept 2007 | - | $347.00 K(-87.9%) | $185.30 M(-0.4%) |
| June 2007 | - | $2.87 M(+46.4%) | $186.02 M(+1.1%) |
| Mar 2007 | - | $1.96 M(-98.9%) | $183.94 M(-0.8%) |
| Dec 2006 | $185.40 M(+4443.0%) | $180.13 M(>+9900.0%) | $185.40 M(+2152.2%) |
| Sept 2006 | - | $1.07 M(+36.0%) | $8.23 M(+13.5%) |
| June 2006 | - | $787.00 K(-77.0%) | $7.25 M(+12.1%) |
| Mar 2006 | - | $3.42 M(+15.4%) | $6.47 M(+58.5%) |
| Dec 2005 | $4.08 M(-8.1%) | $2.96 M(+3187.8%) | $4.08 M(+110.3%) |
| Sept 2005 | - | $90.00 K(+4400.0%) | $1.94 M(+86.1%) |
| June 2005 | - | $2000.00(-99.8%) | $1.04 M(-23.9%) |
| Mar 2005 | - | $1.03 M(+25.8%) | $1.37 M(-69.2%) |
| Dec 2004 | $4.44 M(-95.9%) | $819.00 K(-201.4%) | $4.44 M(-45.9%) |
| Sept 2004 | - | -$808.00 K(-345.6%) | $8.21 M(-86.0%) |
| June 2004 | - | $329.00 K(-92.0%) | $58.54 M(-8.2%) |
| Mar 2004 | - | $4.10 M(-10.6%) | $63.79 M(-41.0%) |
| Dec 2003 | $108.18 M(+6178.8%) | $4.59 M(-90.7%) | $108.18 M(+3.8%) |
| Sept 2003 | - | $49.52 M(+788.1%) | $104.19 M(+90.8%) |
| June 2003 | - | $5.58 M(-88.5%) | $54.62 M(+11.1%) |
| Mar 2003 | - | $48.50 M(+8064.5%) | $49.16 M(+2753.3%) |
| Dec 2002 | $1.72 M(-99.5%) | $594.00 K(-1337.5%) | $1.72 M(-99.1%) |
| Sept 2002 | - | -$48.00 K(-140.0%) | $192.41 M(-0.2%) |
| June 2002 | - | $120.00 K(-88.6%) | $192.85 M(-1.6%) |
| Mar 2002 | - | $1.06 M(-99.4%) | $196.03 M(-43.9%) |
| Dec 2001 | $349.12 M(+275.9%) | $191.28 M(>+9900.0%) | $349.12 M(+121.4%) |
| Sept 2001 | - | $398.00 K(-87.9%) | $157.68 M(-9.8%) |
| June 2001 | - | $3.29 M(-97.9%) | $174.84 M(-28.4%) |
| Mar 2001 | - | $154.15 M(<-9900.0%) | $244.34 M(+163.1%) |
| Dec 2000 | $92.87 M(>+9900.0%) | -$161.00 K(-100.9%) | $92.87 M(-0.4%) |
| Sept 2000 | - | $17.55 M(-75.9%) | $93.23 M(+23.7%) |
| June 2000 | - | $72.80 M(+2621.4%) | $75.37 M(+3073.6%) |
| Mar 2000 | - | $2.67 M(+1237.5%) | $2.38 M(+691.7%) |
| Dec 1999 | $300.00 K(-121.4%) | $200.00 K(-166.7%) | $300.00 K(-250.0%) |
| Sept 1999 | - | -$300.00 K(+50.0%) | -$200.00 K(0.0%) |
| June 1999 | - | -$200.00 K(-133.3%) | -$200.00 K(-33.3%) |
| Mar 1999 | - | $600.00 K(-300.0%) | -$300.00 K(-78.6%) |
| Dec 1998 | -$1.40 M(-103.6%) | -$300.00 K(0.0%) | -$1.40 M(-36.4%) |
| Sept 1998 | - | -$300.00 K(0.0%) | -$2.20 M(-15.4%) |
| June 1998 | - | -$300.00 K(-40.0%) | -$2.60 M(-106.5%) |
| Mar 1998 | - | -$500.00 K(-54.5%) | $39.90 M(+1.3%) |
| Dec 1997 | $39.40 M(-40.6%) | -$1.10 M(+57.1%) | $39.40 M(-21.2%) |
| Sept 1997 | - | -$700.00 K(-101.7%) | $50.00 M(+0.4%) |
| June 1997 | - | $42.20 M(-4320.0%) | $49.80 M(-23.5%) |
| Mar 1997 | - | -$1.00 M(-110.5%) | $65.10 M(-1.8%) |
| Dec 1996 | $66.30 M(+233.2%) | $9.50 M(-1155.6%) | $66.30 M(-15.6%) |
| Sept 1996 | - | -$900.00 K(-101.6%) | $78.60 M(-0.3%) |
| June 1996 | - | $57.50 M(>+9900.0%) | $78.80 M(+282.5%) |
| Mar 1996 | - | $200.00 K(-99.1%) | $20.60 M(+3.5%) |
| Dec 1995 | $19.90 M(<-9900.0%) | $21.80 M(-3214.3%) | $19.90 M(-5075.0%) |
| Sept 1995 | - | -$700.00 K(0.0%) | -$400.00 K(0.0%) |
| June 1995 | - | -$700.00 K(+40.0%) | -$400.00 K(-20.0%) |
| Mar 1995 | - | -$500.00 K(-133.3%) | -$500.00 K(+150.0%) |
| Dec 1994 | -$200.00 K(-100.4%) | $1.50 M(-314.3%) | -$200.00 K(-91.3%) |
| Sept 1994 | - | -$700.00 K(-12.5%) | -$2.30 M(-104.7%) |
| June 1994 | - | -$800.00 K(+300.0%) | $49.40 M(-1.0%) |
| Mar 1994 | - | -$200.00 K(-66.7%) | $49.90 M(+0.2%) |
| Dec 1993 | $49.80 M(-6325.0%) | -$600.00 K(-101.2%) | $49.80 M(-0.8%) |
| Sept 1993 | - | $51.00 M(<-9900.0%) | $50.20 M(-4663.6%) |
| June 1993 | - | -$300.00 K(0.0%) | -$1.10 M(+10.0%) |
| Mar 1993 | - | -$300.00 K(+50.0%) | -$1.00 M(+25.0%) |
| Dec 1992 | -$800.00 K(-100.9%) | -$200.00 K(-33.3%) | -$800.00 K(+33.3%) |
| Sept 1992 | - | -$300.00 K(+50.0%) | -$600.00 K(+100.0%) |
| June 1992 | - | -$200.00 K(+100.0%) | -$300.00 K(+200.0%) |
| Mar 1992 | - | -$100.00 K | -$100.00 K |
| Dec 1991 | $91.50 M | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly CFF year-on-year change?
- What is Regeneron Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM CFF year-on-year change?
What is Regeneron Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of REGN is -$1.79 B
What is the all time high annual CFF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual cash flow from financing activities is $384.25 M
What is Regeneron Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of REGN is -$634.00 M
What is the all time high quarterly CFF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly cash flow from financing activities is $612.00 M
What is Regeneron Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, REGN quarterly cash flow from financing activities has changed by -$187.90 M (-42.12%)
What is Regeneron Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of REGN is -$1.51 B
What is the all time high TTM CFF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM cash flow from financing activities is $384.25 M
What is Regeneron Pharmaceuticals TTM CFF year-on-year change?
Over the past year, REGN TTM cash flow from financing activities has changed by +$279.00 M (+15.59%)